{"nct_id":"NCT02927769","title":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","status":"COMPLETED","status_verified_date":"2025-01","start_date":"2017-03-28","start_date_type":"ACTUAL","primary_completion_date":"2024-05-28","primary_completion_date_type":"ACTUAL","completion_date":"2024-05-28","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["BMY"]}